Official: THE LEHMAN TRILOGY to play the Nederlander this Spring

Woohoo! So exciting to have such high-caliber work continue to appear on Broadway, continuously raising the bar. This is one of the few shows I've seen where I genuinely have no idea how these actors perform 8x/week in this mammoth, exhausting show. Props to them.

If you're a fan of theatre, don't miss this.

So glad I got to see this at the Armory, where the ultra-wide staging was able to make spectacular use of the projections. From the pics I've seen of the current production in London, the transition to a standard proscenium theatre makes it look cramped, to say the least.

Updated On: 9/3/19 at 11:48 AM

So excited for this one!

I saw it at the Piccadilly and it didn't feel cramped at all, I imagine they'll use the Piccadilly set for the Broadway run.

When I looked a that photo, I immediately thought that it looks very cramped, but that's probably because the Armory staging is so fixed in my head. When you think about it, the show really doesn't NEED all of that vast, empty space.

And as Mike Barrett pointed out, the Nederlander stage is probably larger and wider (in fact, I've found that most of the older West End theatres tend to be on the narrow side compared to Broadway theatres.

So happy. I adore Ben Miles and was bummed to miss this at the Armory.

To anyone who didn't see it at the Armory, I'm sure it doesn't looked cramped at the Piccadilly. My point was that, by comparison, it looks cramped. At the Armory, part of what made the projections so effective was how they reflected on the expansive stage floor, which is a brilliant effect I can imagine is significantly diminished in a smaller space.

Updated On: 9/3/19 at 03:53 PM

So, this will almost certainly be considered a new play for the Tony Awards, and that is probably the correct decision.

BUT, just because I'm in the mood to be nerdy and pedantic, I'd like to point out that the play premiered back in 2013, and had a few productions that were completely unaffiliated with the National Theatre's production. According to Wikipedia, it premiered in France in 2013, which was followed by an Italian production in 2015. It wasn't until fall of 2018 that the National took the existing play, had it translated into English, and re-conceived it into its current form. SO, given that the play had already been produced independently for several years before this production came into being, one could make a case that TECHNICALLY, the National Theatre's production was a revival of Massini's play, and by extension, this Broadway production would be a revival.

But I understand that all this happened in a relatively short span of time, which was probably not long enough to consider something a revival under the "classics" rule. I just think it's kind of an interesting alternate take on the situation.

Anyway, move along!

imeldasturn said: "Yasmina Reza's Art opened in France in 1994 and on Broadway in 1998, and yet it won Best Play. There's no way Lehman Trilogy will be considered a revival."



And I fully acknowledge that. I know precedent is against it, and it won't happen. But as I said, sometimes I just feel like being overly pedantic about these sorts of things because it's a fun exercise in examining how we classify productions. For example: you could maybe have made the same case about Yasmina Reza's 'art' (depending on if there was any association between the original French premiere and Matthew Warchus' first production)!

I missed this at the Armory and can't seem to make the NT broadcasts at the Symphony Space, so this is good news for this Ben Miles fan.

To those who have seen it - any need to do any background reading to appreciate this play?

I missed this at the Armory, so I'm thrilled about the transfer! I can't imagine the ticket prices will be exorbitant, or at least not nearly as insane as they eventually became at the Armory given the incredibly limited run. I know the reviews and frenzy at the Armory will lead to excitement about the Broadway mounting, but does anyone think this might be a tough sell to the broader public?